DESPINA LALOUDAKIS: Open Payments
NPI 1497727192 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$360 in 18 payments from 9 companies in 2025. Trend: 2023 $77 · 2024 $256 · 2025 $360
Food & beverage: $360
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $76 |
| GlaxoSmithKline, LLC. | 3 | $65 |
| Novartis Pharmaceuticals Corporation | 3 | $52 |
| Astellas Pharma US Inc | 2 | $43 |
| PFIZER INC. | 2 | $43 |
| UCB, Inc. | 1 | $33 |
| Boston Scientific Corporation | 1 | $18 |
| SANOFI-AVENTIS U.S. LLC | 1 | $15 |
| Amgen Inc. | 1 | $15 |
Products named: LEQVIO, TRELEGY ELLIPTA, Veozah, Ozempic, NURTEC ODT, Bimzelx, General - Pain Management, SHINGRIX.
Industry payments across AZ — which companies pay providers there.
